Scinai Registers 2.7M ADSs for Resale — Potential 67% Dilution Overhang
SCNI sits 27% above its 52-week low of $1.43 on light trading volume (0.1× avg).
Summary
Scinai registered 2,706,450 ADSs for resale by YA II PN under its existing Standby Equity Purchase Agreement — a potential 67% dilution overhang. The filing also flags immediate delisting risk under a proposed Nasdaq MVLS rule.
Key Events · Financing and Capital Events · SCNI
-
2.7M ADSs Registered for Resale
F-1 registers 2,706,450 ADSs for resale by YA II PN, Ltd. under the September 10, 2025 Standby Equity Purchase Agreement. If all are issued, they would represent approximately 66.67% of the 1,353,228 ADSs outstanding as of September 23, 2026.
-
Massive Dilution Overhang
The registered ADSs would nearly triple the current ADS count from 1,353,228 to 4,059,678. YA purchases ADSs at 97% of the lowest daily VWAP over a three-day pricing period, meaning the company sells at a discount to already-depressed prices.
-
Immediate Delisting Risk Disclosed
The filing states the company's Market Value of Listed Securities is currently below the proposed $5 million Nasdaq threshold. If the SEC's stay on the new MVLS rule is lifted, the ADSs could face immediate suspension and delisting with no cure period.
-
Going Concern Warning Reiterated
The auditor's report on the consolidated financial statements contains an explanatory paragraph regarding the company's ability to continue as a going concern, incorporated by reference into this registration statement.
Analysis · SCNI · Life Sciences
Scinai filed an F-1 to register 2,706,450 ADSs for resale by YA II PN, Ltd. under the September 2025 Standby Equity Purchase Agreement. If all registered ADSs are issued, they would represent roughly 67% of the current 1,353,228 ADSs outstanding — a massive dilution overhang for a company with a market cap near $1.1 million. The filing also discloses that the company's Market Value of Listed Securities is currently below the proposed $5 million Nasdaq threshold, meaning the ADSs could face immediate suspension and delisting if the SEC's stay on that rule is lifted. Against the backdrop of the company's going-concern warning and recent 1-for-10 reverse split, this registration signals continued reliance on deeply discounted equity financing to fund operations.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 36.8% of the 988 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.55%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SCNI was trading at $1.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1M. The 52-week trading range was $1.43 to $16.30. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.